Efficacy of recombinant human thrombopoietin in patients with acute-on-chronic liver failure and thrombocytopenia: A prospective, open-label study

Table 2 Dynamic changes in serum platelet count and white blood cell levels in the recombinant human thrombopoietin and control groups, n (%)

Variables	rhTPO (n = 35)	Control (n = 35)	P value1
The proportion of patients with platelet count > 50 × 109/L on day 14
Baseline	3 (8.6)	2 (5.7)	1.000
Day 7	8 (22.9)	8 (27.6)	0.664
Day 14	17 (60.7)	3 (12.0)	< 0.001
Platelet count, 109/L
Baseline	28 (19, 39)	35 (24, 42)	0.213
Day 7	34 (20, 50)a	37 (27, 53)a	0.274
Day 7 change from baseline	3.0 (-3.0, 18.0)	3.0 (-2.5, 26.5)	0.956
Day 14	64 (33, 91)a	33 (24, 42)	0.005
Day 14 change from baseline	24.5 (4.0, 47.0)	0 (-11.0, 13.0)	< 0.001
WBC, 109/L
Baseline	2.5 (1.9, 5.3)	4.8 (3.1, 8.2)	< 0.001
Day 7	3.0 (2.2, 4.4)	4.5 (2.9, 6.8)	0.016
Day 7 change from baseline	0.21 (-0.45, 0.80)	-0.22 (-2.27, 0.49)	0.275
Day 14	4.0 (2.3, 5.4)	3.3 (2.6, 5.3)a	0.695
Day 14 change from baseline	0.11 (-0.90, 2.24)	-0.67 (-2.14, 0.00)	0.019

^aP < 0.05 indicates statistically significant differences comparing with baseline.

¹P value indicates the comparison of variables between recombinant human thrombopoietin group and control group.

Values are expressed as median. rhTPO: Recombinant human thrombopoietin; WBC: White blood cell count.